Results 111 to 120 of about 16,909 (214)
British Journal of Haematology, Volume 208, Issue 6, Page 2320-2325, June 2026.
Barbara Gianesin +29 more
wiley +1 more source
A hallmark of diabetes mellitus is the breakdown of almost every reparative process in the human body, leading to critical impairments of wound healing. Stabilization and activity of the transcription factor hypoxia-inducible factor (HIF)-1?
Duscher, Dominik;Januszyk, Michael;Maan, Zeshaan N;Whittam, Alexander J;Hu, Michael S;Walmsley, Graham G;Dong, Yixiao;Khong, Sacha M;Longaker, Michael T;Gurtner, Geoffrey C
core +1 more source
Eleven minutes of complete cerebral ischemia was produced in 17 dogs by temporary ligation of the venae cavae and aorta. Immediately prior to the ischemic episode, 7 dogs received deferoxamine, an iron chelator, 50 mg/kg i.v., and 10 dogs received an ...
W L Lanier +3 more
core +1 more source
Effect of Deferoxamine on Late Deaths Following CPR in Rats
The iron chelating agent deferoxamine was studied in an animal model as post-resuscitation therapy to prevent late deaths and brain damage following total circulatory arrest and resuscitation. Cardio-respiratory arrest was induced by injection of cold, 1%
Babbs, Charles F +2 more
core
Intracerebral hemorrhage (ICH) is a most serious type of hemorrhagic stroke with a continuously rising incidence globally, without effective cure available.
Yulin Liu +5 more
doaj +1 more source
Effect of intravenous Deferoxamine concomitant use with blood transfusion on serum ferritin in thalassemia major patients [PDF]
Background: Subcutaneous Deferoxamineis often not tolerated by patients and its rejection leads to iron overload with its complications. So, other methods with better toleration and reduction of Deferoxamine consumption are necessary. The present study
عرقچین, سمیرا +3 more
core
The impact of intravenous deferoxamine during the blood transfusion on reduction of serum ferritin in thalassemia patients [PDF]
Introduction: A blood transfusion in patients with thalassemia major is a important treatment base. Iron overload resulted from Long-term transfusion-related using iron chelators particularly by the deferoxamine can be reduced.
عرقچین, سمیرا +2 more
core
Background: Hearing disorders are reported in thalassemia patients treated with deferoxamine. This study aimed to assess hearing loss in Iranian thalassemia major patients treated with deferoxamine.
Gholamreza Badfar +9 more
doaj
Comparative evaluation of microfluidic-synthesized nano-niosomes versus liposomal and micro-niosomal deferoxamine in murine iron overload models. [PDF]
Bazi A +6 more
europepmc +1 more source

